131 related articles for article (PubMed ID: 12191968)
21. Globotriaosylceramide induces lysosomal degradation of endothelial KCa3.1 in fabry disease.
Choi S; Kim JA; Na HY; Cho SE; Park S; Jung SC; Suh SH
Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):81-9. PubMed ID: 24158513
[TBL] [Abstract][Full Text] [Related]
22. Transmembrane BAX inhibitor motif containing (TMBIM) family proteins perturbs a trans-Golgi network enzyme, Gb3 synthase, and reduces Gb3 biosynthesis.
Yamaji T; Nishikawa K; Hanada K
J Biol Chem; 2010 Nov; 285(46):35505-18. PubMed ID: 20837469
[TBL] [Abstract][Full Text] [Related]
23. Different binding property of verotoxin-1 and verotoxin-2 against their glycolipid receptor, globotriaosylceramide.
Itoh K; Tezuka T; Inoue K; Tada H; Suzuki T
Tohoku J Exp Med; 2001 Dec; 195(4):237-43. PubMed ID: 11908825
[TBL] [Abstract][Full Text] [Related]
24. Shiga toxin-1 regulation of cytokine production by human proximal tubule cells.
Hughes AK; Stricklett PK; Kohan DE
Kidney Int; 1998 Oct; 54(4):1093-106. PubMed ID: 9767525
[TBL] [Abstract][Full Text] [Related]
25. Recruitment of renal tubular epithelial cells expressing verotoxin-1 (Stx1) receptors in HIV-1 transgenic mice with renal disease.
Liu XH; Lingwood CA; Ray PE
Kidney Int; 1999 Feb; 55(2):554-61. PubMed ID: 9987079
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.
Eng CM; Guffon N; Wilcox WR; Germain DP; Lee P; Waldek S; Caplan L; Linthorst GE; Desnick RJ;
N Engl J Med; 2001 Jul; 345(1):9-16. PubMed ID: 11439963
[TBL] [Abstract][Full Text] [Related]
27. The Shiga Toxin Receptor Globotriaosylceramide as Therapeutic Target in Shiga Toxin
Feitz WJC; Bouwmeester R; van der Velden TJAM; Goorden S; Licht C; van den Heuvel LPJW; van de Kar NCAJ
Microorganisms; 2021 Oct; 9(10):. PubMed ID: 34683478
[TBL] [Abstract][Full Text] [Related]
28. A glucosylceramide synthase inhibitor protects rats against the cytotoxic effects of shiga toxin 2.
Silberstein C; Lucero MS; Zotta E; Copeland DP; Lingyun L; Repetto HA; Ibarra C
Pediatr Res; 2011 May; 69(5 Pt 1):390-4. PubMed ID: 21270676
[TBL] [Abstract][Full Text] [Related]
29. Caveolin-associated accumulation of globotriaosylceramide in the vascular endothelium of alpha-galactosidase A null mice.
Shu L; Shayman JA
J Biol Chem; 2007 Jul; 282(29):20960-7. PubMed ID: 17535804
[TBL] [Abstract][Full Text] [Related]
30. Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types.
Welford RWD; Mühlemann A; Garzotti M; Rickert V; Groenen PMA; Morand O; Üçeyler N; Probst MR
Hum Mol Genet; 2018 Oct; 27(19):3392-3403. PubMed ID: 29982630
[TBL] [Abstract][Full Text] [Related]
31. Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease.
Sueoka H; Aoki M; Tsukimura T; Togawa T; Sakuraba H
PLoS One; 2015; 10(12):e0144958. PubMed ID: 26661087
[TBL] [Abstract][Full Text] [Related]
32. A symptomatic Fabry disease mouse model generated by inducing globotriaosylceramide synthesis.
Taguchi A; Maruyama H; Nameta M; Yamamoto T; Matsuda J; Kulkarni AB; Yoshioka H; Ishii S
Biochem J; 2013 Dec; 456(3):373-83. PubMed ID: 24094090
[TBL] [Abstract][Full Text] [Related]
33. A novel, promoter-based, target-specific assay identifies 2-deoxy-D-glucose as an inhibitor of globotriaosylceramide biosynthesis.
Okuda T; Furukawa K; Nakayama K
FEBS J; 2009 Sep; 276(18):5191-202. PubMed ID: 19674101
[TBL] [Abstract][Full Text] [Related]
34. Globotriaosylceramide leads to K(Ca)3.1 channel dysfunction: a new insight into endothelial dysfunction in Fabry disease.
Park S; Kim JA; Joo KY; Choi S; Choi EN; Shin JA; Han KH; Jung SC; Suh SH
Cardiovasc Res; 2011 Feb; 89(2):290-9. PubMed ID: 20971723
[TBL] [Abstract][Full Text] [Related]
35. Epithelial-Mesenchymal Transition in Kidney Tubular Epithelial Cells Induced by Globotriaosylsphingosine and Globotriaosylceramide.
Jeon YJ; Jung N; Park JW; Park HY; Jung SC
PLoS One; 2015; 10(8):e0136442. PubMed ID: 26291612
[TBL] [Abstract][Full Text] [Related]
36. Up-regulation of tissue factor activity on human proximal tubular epithelial cells in response to Shiga toxin.
Nestoridi E; Kushak RI; Duguerre D; Grabowski EF; Ingelfinger JR
Kidney Int; 2005 Jun; 67(6):2254-66. PubMed ID: 15882267
[TBL] [Abstract][Full Text] [Related]
37. Trafficking of Shiga toxin/Shiga-like toxin-1 in human glomerular microvascular endothelial cells and human mesangial cells.
Warnier M; Römer W; Geelen J; Lesieur J; Amessou M; van den Heuvel L; Monnens L; Johannes L
Kidney Int; 2006 Dec; 70(12):2085-91. PubMed ID: 17063173
[TBL] [Abstract][Full Text] [Related]
38. Chemokine expression in human astrocytes in response to shiga toxin 2.
Kioka N; Minami K; Tamura A; Yoshikawa N
Int J Inflam; 2012; 2012():135803. PubMed ID: 23304632
[TBL] [Abstract][Full Text] [Related]
39. Oral therapeutic agents with highly clustered globotriose for treatment of Shiga toxigenic Escherichia coli infections.
Watanabe M; Matsuoka K; Kita E; Igai K; Higashi N; Miyagawa A; Watanabe T; Yanoshita R; Samejima Y; Terunuma D; Natori Y; Nishikawa K
J Infect Dis; 2004 Feb; 189(3):360-8. PubMed ID: 14745692
[TBL] [Abstract][Full Text] [Related]
40. Shiga toxin-1 regulation of cytokine production by human glomerular epithelial cells.
Hughes AK; Stricklett PK; Kohan DE
Nephron; 2001 May; 88(1):14-23. PubMed ID: 11340345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
